П

## FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Check this box if no longer subje	ct to
Section 16. Form 4 or Form 5	
obligations may continue. See	
Instruction 1(b).	

## STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

# OMB APPROVAL OMB Number: 3235-0287

Estimated average burden hours per response: 0.5

1. Name and Address of Reporting Person <sup>*</sup> <u>SQUINTO STEPHEN P</u>			2. Issuer Name <b>and</b> Ticker or Trading Symbol <u>ALEXION PHARMACEUTICALS INC</u> [ ALXN]		ationship of Reporting Person(s) to Issuer k all applicable) Director 10% Owner Officer (give title Other (specifi below) below)	
(Last)	(First)	(Middle)	3. Date of Earliest Transaction (Month/Day/Year)	7	EVP, Chief Global	Ops. Officer
C/O ALEXION PHARMACEUTICALS INC			07/12/2013			•
352 KNOTTE	R DRIVE					
			4. If Amendment, Date of Original Filed (Month/Day/Year)		vidual or Joint/Group Filin	g (Check Applicable
(Street)				Line)		
CHESHIRE	СТ	06410		X	Form filed by One Rep	orting Person
					Form filed by More tha Person	In One Reporting
(City)	(State)	(Zip)				

#### Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transa Code ( 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)	
			Code	v	Amount	(A) or Transaction(s)			(1130.4)		
Common Stock, par value .0001 per share	07/12/2013		М		<b>6,8</b> 76 <sup>(1)</sup>	Α	\$17.98	115,338	D		
Common Stock, par value .0001 per share	07/12/2013		М		11,124 <sup>(1)</sup>	A	\$22.9	126,462	D		
Common Stock, par value .0001 per share	07/12/2013		S		18,000(1)	D	\$119.9	108,462	D		

### Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transa Code ( 8)		of		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				
Option to Purchase Common Stock	\$17.98	07/12/2013		S			6,876	04/26/2009	01/26/2019	Common Stock	6,876	\$17.98	0	D	
Option to Purchase Common Stock	\$22.9	07/12/2013		s			11,124	04/28/2010	01/28/2020	Common Stock, par value \$.0001 per share	11,124	\$22.9	0	D	

#### Explanation of Responses:

1. The transactions reported by this Form 4 are made pursuant to the terms of a sales plan designed to meet the requirements of Rule 10b5-1(c)(1) of the Securities Exchange Act.

**Remarks:** 

/s/ Stephen Squinto

07/16/2013

Date

\*\* Signature of Reporting Person

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.